These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26315810)

  • 41. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.
    Teng R; Mitchell PD; Butler K
    J Clin Pharm Ther; 2012 Aug; 37(4):464-8. PubMed ID: 21967645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.
    Adamski P; Ostrowska M; Sikora J; Obońska K; Buszko K; Krintus M; Sypniewska G; Marszałł MP; Koziński M; Kubica J
    BMJ Open; 2017 Apr; 7(4):e013218. PubMed ID: 28446521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
    Laine M; Gaubert M; Frère C; Peyrol M; Thuny F; Yvorra S; Chelini V; Bultez B; Luigi S; Mokrani Z; Bessereau J; Toesca R; Champenois A; Dignat-George F; Paganelli F; Bonello L
    Platelets; 2015; 26(6):570-2. PubMed ID: 25275609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study.
    Alexopoulos D; Makris G; Xanthopoulou I; Patsilinakos S; Deftereos S; Gkizas V; Perperis A; Karanikas S; Angelidis C; Tsigkas G; Koutsogiannis N; Hahalis G; Davlouros P
    Circ Cardiovasc Interv; 2014 Apr; 7(2):233-9. PubMed ID: 24668226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
    Monitillo F; Iacoviello M; Caldarola P; Valle R; Chiatto M; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):977-93. PubMed ID: 25882759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
    Butler K; Teng R
    J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
    Li H; Guo J; Carlson GF; Teng R
    Br J Clin Pharmacol; 2016 Aug; 82(2):352-61. PubMed ID: 27038001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
    Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
    Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facility.
    Lupi A; Schaffer A; Lazzero M; Tessitori M; De Martino L; Rognoni A; Bongo AS; Porto I
    Cardiovasc Revasc Med; 2016 Dec; 17(8):528-534. PubMed ID: 27666002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
    JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
    Storey RF; Angiolillo DJ; Bonaca MP; Thomas MR; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Mar; 67(10):1145-1154. PubMed ID: 26965534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
    Yang A; Pon Q; Lavoie A; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Lavi S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN; Dehghani P
    J Thromb Thrombolysis; 2018 Feb; 45(2):225-233. PubMed ID: 29170875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The MOVEMENT Trial.
    Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J
    J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
    Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
    Teng R; Kujacic M; Hsia J
    Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.
    Teng R; Mitchell P; Butler K
    Eur J Clin Pharmacol; 2013 Apr; 69(4):877-83. PubMed ID: 23093043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
    Perla HT; Thomson VS; Attumalil TV; Geevar T; Alex AG; Dave RG; Nair SC; Gowri SM; Mony PK; George P; Joseph G
    Am J Cardiovasc Drugs; 2023 Jul; 23(4):455-466. PubMed ID: 37351814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.